The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when co-administered with the high dose quadrivalent influenza (FLU HD) vaccine in adults aged 65 years and above compared to separate administration of the vaccines.
2 Primary · 12 Secondary · Reporting Duration: Within 4 days (the day of vaccination and 3 subsequent days) after each vaccination (administered on Day 1 and 31)
1028 Total Participants · 2 Treatment Groups
Primary Treatment: Co-Ad Group · No Placebo Group · Phase 3
Age 65+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: